Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators.

PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.

2.

HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators.

Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.

3.

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group.

Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4.

PMID:
25103176
4.

Oesophageal varices, schistosomiasis, and mortality among patients admitted with haematemesis in Mwanza, Tanzania: a prospective cohort study.

Chofle AA, Jaka H, Koy M, Smart LR, Kabangila R, Ewings FM, Mazigo HD, Johnson WD Jr, Fitzgerald DW, Peck RN, Downs JA.

BMC Infect Dis. 2014 Jun 3;14:303. doi: 10.1186/1471-2334-14-303.

5.

HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE; SPARTAC Trial Investigators.

AIDS. 2014 Mar 13;28(5):699-708. doi: 10.1097/QAD.0000000000000130.

PMID:
24549145
6.

Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models.

Ewings FM, Ford D, Walker AS, Carpenter J, Copas A.

Epidemiology. 2014 Mar;25(2):194-202. doi: 10.1097/EDE.0000000000000043.

7.

Deciphering the complex distribution of human immunodeficiency virus type 1 subtypes among different cohorts in Northern Tanzania.

Njai HF, Ewings FM, Lyimo E, Foulongne V, Ngerageza D, Mongi A, Ssemwanga D, Andreasen A, Nyombi B, Ao T, Michael D, Urassa M, Todd J, Zaba B, Changalucha J, Hayes R, Kapiga SH.

PLoS One. 2013 Dec 11;8(12):e81848. doi: 10.1371/journal.pone.0081848. eCollection 2013.

8.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators.

AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.

PMID:
24300544
9.

The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania.

Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, Baisley K, Francis S, Andreasen A, Hashim R, Watson-Jones D, Changalucha J, Hayes R.

PLoS One. 2013 Jul 18;8(7):e68825. doi: 10.1371/journal.pone.0068825. Print 2013.

10.

Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.

Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN, McClure MO, Kellam P; SPARTAC Trial Investigators.

Retrovirology. 2013 Jan 18;10:8. doi: 10.1186/1742-4690-10-8.

11.

Short-course antiretroviral therapy in primary HIV infection.

SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.

N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.

12.

Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection.

Yager N, Robinson N, Brown H, Flanagan P, Frater J, Fidler S, Weber J, Phillips R; SPARTAC Trial Investigators.

AIDS. 2013 Jan 28;27(3):313-23. doi: 10.1097/QAD.0b013e32835b8cf5.

PMID:
23095315
13.

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators.

PLoS One. 2012;7(8):e43754. Epub 2012 Aug 31.

14.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2012 Aug 24;26(13):1691-705.

15.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

16.

Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.

Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S, McClure M, Fidler S; SPARTAC Investigators.

AIDS. 2012 Apr 24;26(7):887-90. doi: 10.1097/QAD.0b013e328351e721.

PMID:
22313951
17.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

18.

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.

Burger D, Ewings F, Kabamba D, L'homme R, Mulenga V, Kankasa C, Thomason M, Gibb DM, Chintu C, Walker AS.

Ther Drug Monit. 2010 Jun;32(3):369-72. doi: 10.1097/FTD.0b013e3181d75e47.

PMID:
20386361
19.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

20.

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.

L'homme RF, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, Walker AS, Chintu C, Burger DM, Gibb DM.

AIDS. 2008 Mar 12;22(5):557-65. doi: 10.1097/QAD.0b013e3282f4a208.

PMID:
18316996
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk